Skip to main navigation Skip to search Skip to main content

Microrobotic copper-rich electrochemical interfacing for targeted cancer theranostics in the gut

  • Junghwan Byun* (Co-first Author)
  • , Siyeon Jang (Co-first Author)
  • , Yingdan Wu (Co-first Author)
  • , Jiwoong Choi (Co-first Author)
  • , Ugur Bozuyuk
  • , Junghyeon Ko
  • , Alp Can Karacakol
  • , Eun Hye Kim
  • , Sungwoo Chun
  • , Amirreza Aghakhani
  • , Seungjun Chung
  • , Jiachen Zhang
  • , Yoosoo Yang*
  • , Metin Sitti*
  • *Corresponding author for this work

Research output: Journal Publications and ReviewsRGC 21 - Publication in refereed journalpeer-review

2 Downloads (CityUHK Scholars)

Abstract

The exquisite spatiotemporal regulation of drug biodistribution is paramount for optimal targeted cancer theranostics. Robotic ingestible devices promise to reinvent the way drugs interact with gastrointestinal (GI) tissues and malignant tumors. However, no study has yet demonstrated theranostic functions beyond merely conveying synthetic drugs. Here, we present an orally administrable, functionally integrated soft microrobot capable of localized therapeutic regulation of copper (Cu)–dependent cell death mechanism, termed “cuproptosis” within GI tumors. By leveraging the interplay of mechanical, electrical, and biochemical functions, the robot actively targets and grasps the tumor and generates anticancer Cu-rich electrochemical interfacing with the targeted tumor microenvironment. This tumor-robot interface, characterized by in situ generated electric multipole fields and on-demand burst Cu2+ ion release, induces ~104-fold increase in local concentration of Cu2+ ions, and drives their dense accumulation and directed infiltration for effective cuproptotic cancer treatment, with tumor penetration capabilities far beyond those of passive diffusion. Demonstrations of minimally invasive, long-range tumor targeting in porcine organs and mouse tumor eradication in vivo demonstrate the translational potential of our approach as microrobotic theranostic platforms for targeting GI cancer.
Original languageEnglish
Article numbereaeb5934
Number of pages17
JournalScience Advances
Volume12
Issue number11
Online published13 Mar 2026
DOIs
Publication statusPublished - 13 Mar 2026

Funding

This work was supported by the Max Planck Society, European Research Council (ERC) Advanced Grant SoMMoR project with grant no. 834531 (to M.S. and Y.W.), the Max Planck ETH Center for Learning Systems (to M.S. and S.J.), the Nano & Material Technology Development Program through the National Research Foundation of Korea (NRF) funded by Ministry of Science and ICT (no. RS-2024-00407155 to J.B.) and the Korea government (MSIT) (no. RS-2023-00211936) (to J.B.), and the Korea Institute of Science and Technology (KIST) Future Resource Research Program (no. 2E33853 to J.B.). Y.W. appreciated the financial support from the National Key Research and Development Program of China (no. 2024YFB3409400), the National Natural Science Foundation of China (nos. 52405613 and 52125505), and Self-Planned Task (no. SKLRS202403C) of State Key Laboratory of Robotics and Systems (HIT).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Publisher's Copyright Statement

  • This full text is made available under CC-BY 4.0. https://creativecommons.org/licenses/by/4.0/

Fingerprint

Dive into the research topics of 'Microrobotic copper-rich electrochemical interfacing for targeted cancer theranostics in the gut'. Together they form a unique fingerprint.

Cite this